Clinical trialRSSApr 28
FX activator may help with bleeding control in hemophilia A and B: Trials
Researchers tested a new medicine called bemiltenase alfa that helps control bleeding in people with hemophilia A and B. These patients had developed resistance to standard treatments, making their bleeding harder to manage. Early trial results show this new medicine may help them control bleeding when it happens.
WHY IT MATTERSFor hemophilia patients who have developed inhibitors (antibodies that block standard treatments), bemiltenase alfa offers a potential new option for on-demand bleeding control when current therapies no longer work effectively.